Helen M. Colhoun - Concepedia

Author

Helen M. Colhoun

Also Known As

A.D. Morris, Adrienne Kirby, Alexander P. Maxwell, Colhoun, H, Colhoun, H.M., Colhoun, HM, Colhoun, Helen M, Colhoun, Helen M., D. Gogas, GENIE Consortium,

514

Publications

40.3K

Citations

H-Index

166

Concepts

All Affiliations

University of Edinburgh University of Dundee University of Glasgow University College London Western General Hospital

About

Helen M. Colhoun is an author at University of Edinburgh specializing in medicine, diabetes, and public health.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	36	58	9K
2	Public Health	27	42	9.5K
3	Health Sciences	4	4	441
4	Natural Sciences	1	1	52
5	Allergy	1	1	1.3K

Helen M. Colhoun

224

Publications

28.6K

Citations

H-Index

Page 1

	Year	Citations
Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial Helen M. Colhoun, D. J. Betteridge, Paul N. Durrington, The Lancet Metabolic SyndromePrimary PreventionDiabetes ManagementHealth PolicyCardiovascular Disease	2004	3.8K
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais, The Lancet Metabolic SyndromeDiabetes ManagementCardiovascular DiseaseHealth PolicyCardiovascular Outcomes	2019	2.8K
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes A. Michael Lincoff, Kirstine Brown‐Frandsen, Helen M. Colhoun, New England Journal of Medicine	2023	2.1K
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial Paul M. Ridker, Jean MacFadyen, Tom Thurén, The Lancet InflammationAllergyLung InflammationMedicineMetronomic Therapy	2017	1.3K
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais, The Lancet Metabolic SyndromeDiabetes ManagementUrologyChronic Kidney DiseaseDiabetes	2019	600
Estimated Life Expectancy in a Scottish Cohort With Type 1 Diabetes, 2008-2010 Shona Livingstone, Daniel L. Levin, Helen C. Looker, JAMA	2015	594
Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial Christopher P. Cannon, Bertrand Cariou, Dirk Blom, European Heart Journal	2015	394
High Risk of Cardiovascular Disease in Patients With Type 1 Diabetes in the U.K. Sabita S. Soedamah‐Muthu, John Fuller, Henrietta Mulnier, Diabetes Care	2006	386
Risk of hospital admission with coronavirus disease 2019 in healthcare workers and their households: nationwide linkage cohort study Anoop Shah, Rachael Wood, Ciara Gribben, BMJ	2020	377
Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study Dean J. Kereiakes, Jennifer G. Robinson, Christopher P. Cannon, American Heart Journal	2015	342

Page 1